Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News 1st GBHI-Conference – Conference Report now available 3rd GBHI conference – program is online Who is a healthy subject? German Pharm-Tox Summit 2017 in Heidelberg 2nd part of Introductory Course in Exploratory Medicines Development scheduled for February 2017 Introductory Course in Exploratory Medicines Development – taking place in our offices in Oberursel! Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
Pharmacology Biopharmaceutics Xerostomia PASS Charcoal Early phase Children Macular Lung CDISC Endpoint MDI Competence TTS MMM Protocol Thuringia Sample size estimation Phase I Dry powder inhaler GCP Intensive assessment station AGAH Statistical programming Cardiovascular surveillance Spacious archive SocraTec C&S Phase IIb trials Ophthalmology CDSIC Safety Sore throat GLP MCID Creativity Ovulation inhibition Anaesthesiologist Common cold DFI Postmenopausal women Ophthalmologist Eye disease Monitoring Dose linearity GCP training Absorption ANVISA Pragmatism Hypothalamic Statistical Analysis Plan Oncology Clinical study Biopharmaceutical SOP based Oncological patients Biometrics Adrenocortical Data Validation Plan Good Clinical Practice Pilot study Post authorisation Asthma DDI Standardisation HPA axis Protocol development Project Management CRF Steady state Clinical trials Feasibility Metered dose inhaler Pharmacodynamic studies Recruitment rates FDA Degeneration DUS Data Management Plan SAS Dermal irritation Immunogenicity Quality Expert Patients IEC Scientific expertise Authorities Transdermal therapeutic system Phase III Uveitis CDASH Subcontractor qualification Audit Oncologic network Pituitary Scientific advice PAES Gynaecological trials Patient recruitment Copyright Non interventional Data management Rhine Main area Slit lamp microscopy Hormone replacement therapy Contraception Informed Consent Procedure Ophthalmological trials Quality Assurance FIM IMPD Patch Standard operating procedure In vitro in vivo correlation Local tolerability OTC US CFR 21 Part 11 Bioequivalence IVIVC Training Phase I Unit NIS Pharmacokintetics HRT Drug Drug Interaction SDV Sensitisation trials US FDA ICF Central surveillance system Axis Dry eye Phase II Patch adhesion Network IB ADAM Clinical Monitoring CRO Bioavailability Glaucoma Sequential designs Database CDM Paediatricians Source Data Verification Biosimilars Elpro Clinical pharmacology unit WinNonlin Auditing Consultancy Female adolescents CRA Phase IIa trials Pulse oximetry plethysmography Highly variable drugs Inspection Edema Cough HTA Centralised procedure Legal representative Absorption windows Quality Management System Legal Information Drug Food Interaction Referral system Ocular tolerability Design development Pharmacokinetics Experience Clinical development program Investigators brochure Allergy First in human Life cycle management COPD EMA Statistical services Healthy subjects Product development Efficacy Inhalatives Phase IV DPI  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page